BackgroundCheck.run
Search For

Xi I Chen, 56Ridgefield, CT

Known as:
Nathan X Chen Xi Shen
Related to:
Yujie W Goodman 51

Xi Chen Phones & Addresses

Ridgefield, CT   

Killingworth, CT   

Lafayette, IN   

Shreveport, LA   

Kenton, DE   

Elk Grove, CA   

Temple, TX   

Sacramento, CA   

Work

Company: University of delaware Dec 2007 Position: Research assistant

Education

School / High School: University of Delaware Jan 2009 Specialities: Certificate in Computational Science and Engineering

Skills

C++ • Matlab • Solidworks • Altium Designer • C# • Lisp • Assembly • AutoCAD • R • Python • Simulink • SQL • Labview • CNC • Mechatronics • Mobile robot planning and control • Haptic feedback • power mobility devices and pediatric walker • Robotic rehabilitation

Ranks

Licence: Illinois - Active And Authorized To Practice Law Date: 2005
Get Report
Control this profile

Mentions for Xi I Chen

Career records & work history

Lawyers & Attorneys

Xi Chen Photo 1

Xi Chen - Lawyer

Address:
365-68634xx (Office)
Licenses:
Illinois - Active And Authorized To Practice Law 2005
Xi Chen Photo 2

Xi Chen - Lawyer

ISLN:
1001069672
Admitted:
2021

Medicine Doctors

Xi Chen

Specialties:
Neurology
Work:
Memorial Sloan Kettering Cancer Center
1275 York Ave, New York, NY 10065
212-6392000 (phone) 646-4220298 (fax)
Education:
Medical School
Fujian Med Coll, Fuzhou City, Fujian, China
Graduated: 1983
Procedures:
Neurological Testing, Sleep and EEG Testing
Conditions:
Hemorrhagic stroke, Myasthenia Gravis (MG), Peripheral Nerve Disorders, Bell's Palsy, Carpel Tunnel Syndrome, Dementia, Epilepsy, Ischemic Stroke, Migraine Headache, Multiple Sclerosis (MS), Obstructive Sleep Apnea, Restless Leg Syndrome, Transient Cerebral Ischemia
Languages:
English
Description:
Dr. Chen graduated from the Fujian Med Coll, Fuzhou City, Fujian, China in 1983. He works in New York, NY and specializes in Neurology. Dr. Chen is affiliated with Bellevue Hospital Center, Memorial Sloan Kettering Cancer Center, New York Presbyterian Hospital Columbia University Medical Center and New York Presbyterian Westchester Division.
Xi Chen Photo 3

Xi Chen

Specialties:
Surgery

Xi Chen resumes & CV records

Resumes

Xi Chen Photo 40

Xi Chen - Newark, DE

Work:
University of Delaware Dec 2007 to Present
Research Assistant Hanyang University Jul 2011 to Aug 2011
Research Consultant University of Delaware Sep 2007 to May 2008
Teaching Assistant Nankai University 2006 to 2007
Research Assistant Nankai University Jun 2005 to Sep 2005
Contestant
Education:
University of Delaware Jan 2009 to Jan 2012
Certificate in Computational Science and Engineering University of Delaware - Newark, DE Jan 2007 to Jan 2012
PhD in Mechanical Engineering Nankai University Jan 2002 to Jan 2006
BE in Automation
Skills:
C++, Matlab, Solidworks, Altium Designer, C#, Lisp, Assembly, AutoCAD, R, Python, Simulink, SQL, Labview, CNC, Mechatronics, Mobile robot planning and control, Haptic feedback, power mobility devices and pediatric walker, Robotic rehabilitation

Publications & IP owners

Us Patents

1-Phenyl-4-Benzylpiperazines Dopamine Receptor Subtype Specific Ligands

US Patent:
6426347, Jul 30, 2002
Filed:
Dec 13, 2000
Appl. No.:
09/736566
Inventors:
Andrew Thurkauf - Danbury CT
Xi Chen - Clinton CT
Assignee:
Neurogen Corporation - Branford CT
International Classification:
C07D295073
US Classification:
51425503, 544392
Abstract:
Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: R is halogen or C -C alkyl; and R and R are the same or different and represent hydrogen, halogen, C -C alkyl, C -C alkoxy, alkylthio, hydroxy, amino, mono(C -C )alkylamino, di(C -C )alkylamino, or R and R together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

N-Aminoalkyldibenzothiopencarboxamide Receptor Subtype Specific Ligands

US Patent:
6429312, Aug 6, 2002
Filed:
Mar 19, 2001
Appl. No.:
09/812199
Inventors:
Jun Yuan - Clinton CT
Xi Chen - New Haven CT
Assignee:
Neurogen Corporation - Branford CT
International Classification:
C07D40914
US Classification:
544295, 544363, 544364, 544375, 544376, 544333, 5462811, 546146, 546175, 546194, 546202, 546256, 549 43, 549 48
Abstract:
Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof, wherein: R , R , R , R are the same or different and represent hydrogen, C -C alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C -C alkoxy, âO CRâ, âNHCORâ, âCORâ, âSO Râ, where Râ is C -C alkyl and wherein m is 0, 1 or 2; or R , R , R , R independently represent âCONRâRâ, or âNRâRâ where Râ and Râ independently represent hydrogen or C -C alkyl; R is hydrogen or C -C alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimers disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

1-Phenyl-4-Benzlpiperazines: Dopamine Receptor Subtype Specific Ligands

US Patent:
6656943, Dec 2, 2003
Filed:
Jun 28, 2002
Appl. No.:
10/186235
Inventors:
Andrew Thurkauf - Danbury CT
Xi Chen - Clinton CT
Assignee:
Neurogen Corporation - Branford CT
International Classification:
A61K 31495
US Classification:
51425503, 544392
Abstract:
Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: R is halogen or C -C alkyl; and R and R are the same or different and represent hydrogen, halogen, C -C alkyl, C -C alkoxy, alkylthio, hydroxy, amino, mono(C -C )alkylamino, di(C -C )alkylamino, or R and R together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

1-Phenyl-4-Benzylpiperazines Dopamine Receptor Subtype Specific Ligands

US Patent:
7101887, Sep 5, 2006
Filed:
Jun 27, 2005
Appl. No.:
11/167735
Inventors:
Andrew Thurkauf - Danbury CT, US
Xi Chen - Clinton CT, US
Assignee:
Neurogen Corporation - Branford CT
International Classification:
A61K 31/495
C07D 295/076
US Classification:
51425503, 544392
Abstract:
Disclosed are compounds of the formula:.

Inhibitors Of Hiv-1 Capsid Formation: Substituted Aryl Aminomethyl Thiazole Ureas And Analogues Thereof

US Patent:
7183300, Feb 27, 2007
Filed:
Nov 10, 2005
Appl. No.:
11/271437
Inventors:
Michael F. Summers - Ellicott City MD, US
Atul Agarwal - Hamden CT, US
Xi Chen - Killingworth CT, US
Milind Deshpande - Madison CT, US
International Classification:
A61K 31/4245
A61K 31/426
A61K 31/341
C07D 271/08
C07D 277/48
C07D 307/54
US Classification:
514364, 514377, 514461, 548125, 548196, 549473
Abstract:
Substituted aryl aminomethyl thiazole ureas and analogues thereof that act as inhibitors of viral capsid formation, including HIV capsid formation, are provided here. Generally the virus capsid formation inhibitors described herein are compounds of Formula I.

Isolated Bos1 Gene Promoters From And Uses Thereof

US Patent:
7230159, Jun 12, 2007
Filed:
Mar 5, 2003
Appl. No.:
10/505744
Inventors:
Tesfaye Mengiste - West Lafayette IN, US
Xi Chen - Research Triangle Park NC, US
John Salmeron - Research Triangle Park NC, US
Robert Dietrich - Research Triangle Park NC, US
Assignee:
Syngenta Participations AG - Basel
International Classification:
C12N 15/82
C12N 15/09
A01H 5/00
US Classification:
800279, 800278, 800298, 536 241, 4353201, 435468
Abstract:
The present invention pertains to an isolated promoter sequence from BOSI gene encoding a protein for biotic and abiotic stress tolerance. Also, the invention relates to recombinant vectors, expression cassettes, host cells, plants or progeny thereof comprising nucleic acid molecules operably linked to said promoter.

1-Phenyl-4-Benzylpiperazines Dopamine Receptor Subtype Specific Ligands

US Patent:
2004008, Apr 29, 2004
Filed:
Sep 22, 2003
Appl. No.:
10/667821
Inventors:
Andrew Thurkauf - Danbury CT, US
Xi Chen - Clinton CT, US
Assignee:
Neurogen Corporation, A Corporation of the State of Delaware - Branford CT
International Classification:
G06F009/44
US Classification:
717/100000, 717/105000
Abstract:
Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: Ris halogen or C-Calkyl; and Rand Rare the same or different and represent hydrogen, halogen, C-Calkyl, C-Calkoxy, alkylthio, hydroxy, amino, mono(C-C)alkylamino, di(C-C)alkylamino, or Rand Rtogether represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

Heteroaryl Guanidines; Inhibitors Of Viral Replication

US Patent:
2006010, May 11, 2006
Filed:
Mar 23, 2005
Appl. No.:
11/088276
Inventors:
Xi Chen - Killingworth CT, US
Andrew Thurkauf - Ridgefield CT, US
Shirley Louise-May - Guilford CT, US
International Classification:
A61K 31/513
A61K 31/505
C07D 239/32
US Classification:
514269000, 514275000, 544320000, 544330000
Abstract:
Compounds of Formula 1, and pharmaceutically acceptable forms thereof, are provided: wherein the variables X, Y, Z, A, R, R, R, Rand Rare defined herein. Certain compounds of Formula 1 described herein which possess potent antiviral activity. Certain compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. Pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are also provided. Methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease or disorder are disclosed. These infectious diseases include viral infections, particularly HCV infections. Methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.

Possible Relatives

Cynthia Chen  David Chen  Cyril X Chen  Cyrus Y Chen  Dawei W Chen  De T Chen  Dafang Chen  Xi W Li  Xi Liu  Xi H Pan 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.